

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.
Question: Should Ivermectin compared to Lopinavir / Ritonavir be used for COVID-19 patients?
Setting: Outpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ivermectina	Lopinavir/Ritonavir	Relative (95% CI)	Absolute (95% CI)	

All-cause mortality

1 ¹	randomised trials	serious _a	not serious	not serious	very serious _b	none	No deaths reported				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------------	--	--	--	------------------

Time to SARS-CoV-2 clearance

1 ¹	randomised trials	serious _a	not serious	not serious	very serious _b	none	42	20	-	SMD 0.77 lower (1.32 lower to 0.22 lower)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	----	----	---	---	------------------

All-cause mortality (Ivermectin 6mg)

1 ¹	randomised trials	serious _a	not serious	not serious	very serious _b	none	No deaths reported				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------------	--	--	--	------------------

Time to SARS-CoV-2 clearance (Ivermectin 6mg)

1 ¹	randomised trials	serious _a	not serious	not serious	very serious _b	none	21	20	-	SMD 0.55 lower (1.18 lower to 0.07 higher)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	----	----	---	--	------------------

All-cause mortality (Ivermectin 12mg)

1 ¹	randomised trials	serious _a	not serious	not serious	very serious _b	none	No deaths reported				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------------	--	--	--	------------------

Time to SARS-CoV-2 clearance (Ivermectin 12mg)

1 ¹	randomised trials	serious _a	not serious	not serious	very serious _b	none	21	20	-	SMD 0.78 lower (1.42 lower to 0.14 lower)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	----	----	---	---	------------------

Explanations

Downgraded of one level for unclear risk of selection and performance bias
 Downgraded of two levels for very small sample size (<100)

References

1. Babalola O, Bode C, Ajayi A, Alakaloko F, Akase I, Otofrowei E, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos. medRxiv. 2021:2021.01.05.21249131